Cerluten®
Distribution of patients by nosological forms, sex and age. Table 1
Diagnosis Age Total: Total: Total:
Control Primary Control Primary Control Primary
Group Group Group Group Group Group
Long-term consequences of 32-58 5 8 2 2 7 10
traumatic brain injury
Conditions after a stroke 51-68 4 4 4 5 8 9
Vascular encephalopathy 52-73 5 6 7 11 12 17
Manifestations of reduced mental 43-65 6 7 4 5 10 12
performance, memory, and
attention
Total: 20 25 17 23 37 48
RESEARCH METHODS
The effectiveness of CERLUTEN® was assessed by the dynamics of subjective indicators and objec-
tively using the methods of correction test and electroencephalography (EEG).
RESEARCH RESULTS
After using CERLUTEN® in patients of the primary group, an excellent clinical result was observed in
64.6% of cases, satisfactory - in 22.9%, no positive effect - in 12.5% of cases (in the control group -
Table 2). There was no negative effect from CERLUTEN® on the condition of the patients.
The efficacy of CERLUTEN® in patients with diseases of the central nervous Table 2
system.
Treatment Results Patient Group
Treatment Using Conventional Means Treatment Using CERLUTEN®
Abs. % Abs. %
Good 10 27,0 31 64,6*
Satisfactory 15 40,5 11 22,9
Unsatisfactory 12 32,5 6 12,5*
Total: 37 100 48 100
* P <0.05 compared with the indicator in patients after treatment with conventional means.
When comparing the subjective indicators of the state of patients before and after the use of CER-
LUTEN®, it was found that the number of health complaints decreased by 2-3 times. Patients noted
an improvement in memory, intelligence, a decrease in the intensity and duration of headaches, the
appearance of emotional balance, volitional qualities, and a sense of rest after a night’s sleep (Table 3).
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.